Details of Drug-Drug Interaction
| Drug General Information (ID: DDIJA6BTXI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Succinylcholine | Drug Info | Physostigmine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Analgesics | Ophthalmic Glaucoma Agents/Antidotes | |||||||
| Structure | |||||||||
| Mechanism of Succinylcholine-Physostigmine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Succinylcholine | Physostigmine | |||||||
| Mechanism |
Neuromuscular blocking agent Acetylcholinesterase Substrate |
Neuromuscular blocking effects Acetylcholinesterase Inhibitor |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Acetylcholinesterase |
×
Structure
Sequence
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKNQFDHYSKQDRCSDL
|
|||||||
| Gene Name | ACHE | ||||||||
| Uniprot ID | ACES_HUMAN | ||||||||
| KEGG Pathway | hsa:43 | ||||||||
| Protein Family | Type-B carboxylesterase/lipase family | ||||||||
| Protein Function |
Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | It may be appropriate to discontinue acetylcholinesterase inhibitor therapy for a few days before the procedure depending on the needs of the patient. Otherwise, the patient should be monitored closely for increased pharmacologic effects of succinylcholine. Peripheral nerve stimulators are recommended for accurate assessment of neuromuscular blockade in patients who have been taking pyridostigmine. | ||||||||